Business Areas

Improving the quality of our lives through state-of-the-art R&D capabilities.
Life science, with outstanding R&D competence and new drugs that have been approved by USFDA for the first time in Korea, is LG Chem’s new growth engine in the mid to long term.
We are aggressively making inroads in overseas markets and expanding pipelines for new drugs through constant investment and reinforcing R&D, with aspirations to become one of the top global pharmaceutical companies.

Sales

Life Science Sales Graph Business Areas LG Chem Life Science Sales Graph Business Areas LG Chem
Sales :2022 ,2023 ,2024
2022 0.9
2023 1.2
2024 1.3

Unit : KRW trillion

  • 2024 Technology export of rare obesity drug to U.S. company 'Rhythm Pharmaceuticals'
  • 2023 Acquired AVEO, a US-based cancer drug company
  • 2022 Launch of the growth hormone treatment Eutropin S PEN
  • 2021 Established a joint venture sales corporation LG Jiansheng Life Sciences in China
  • 2019 Established the Global Innovation Center in Boston, US
  • 2017 Merged with
    LG Life Sciences
  • 2012 Released the first Korean diabetes drug Zemiglo
  • 2003 1st Korean NCE approved by
    USA FDA(Factive)
  • 1996 Won the first prequalification by the WHO with Hepatitis B vaccine Euvax B
  • 1991 Developed World’s first
    4th generation Cephalosporin
  • 1984 Established Pharmaceuticals
    business division
  • 1961 Obtained the drug manufacturing permit

Division

Primary Care Division Business Areas LG Chem Primary Care Division
Specialty Care Division Business Areas LG Chem Specialty Care Division
Aesthetic Division Business Areas LG Chem Aesthetic Division
Go to the related products ▶

VISION

Toward a World-Class Innovative Drug Developer

  • 5 or more innovative new drugs by 2030
  • Enhanced the quality of new drug pipeline
  • Invest over USD 250mil in annual R&D
  • Strengthening of Open innovation
  • Diabetes, metabolic diseases, cancer, autoimmune diseases
  • Expand new drug pipelines in clinical development stage
  • Expand new drug pipelines in clinical development stage :2024 ,2030
    2024 12EA
    2030 20EA

    Explore Research Preclinical Clinical

  • Accelerate clinical developments and business growth worldwide
  • New tasks for global clinical development
  • Continued growth of AVEO's oncology business in the US

LG Chem Life Science Pipeline

  • Diabetes & Metabolism
  • Oncology & Immunology
  • Vaccine
  • Aesthetic
  1. Preclinical(3)
    • LR19128 LR19128Oncology
    • LR20061 LR20061Atopic Dermatitis
    • LR19157 LR19157Oncology
  2. Phase I(7)
    • LR19129 CUE-102Oncology
    • LR19125 PDC*LungNSCLC
    • LR20011 GEN-001Solid tumor
    • AV-380 AV-380Cachexia
    • AV-203 AV-203Oncology
    • LR19155 LR19155Oncology
    • LR19018 LG203003NASH
  3. Phase II(4)
    • LR20062 aP vaccine
    • LR19021 LB54640Genetic Obesity
    • LR19114 6 in 1 Vaccine
    • LR19019 ZectivimodUlcerative colitis Atopic dermatitis
  4. Phase III(2)
  5. NDA(2)
    • LR20024 Y-solution, MDRHA filler
    • LR19094 Y-solution, ChinaHA filler
Image Download 다운로드

Core Products

Eutropin Business Areas LG Chem Eutropin
Hyruan One Business Areas LG Chem Hyruan One
Zemiglo / Zemimet SR Tab. / Zemidapa Business Areas LG Chem Zemiglo / Zemimet SR Tab. / Zemidapa
Eucept Business Areas LG Chem Eucept
YVOIRE Business Areas LG Chem YVOIRE

Press Releases

LG Chem Achieves First Export Milestone for New Diabetes Combination Drug Zemidapa 2025.05.08
LG Chem Achieves First Export Milestone for New Diabetes Combination Drug Zemidapa 2025.05.08
LG Chem Becomes First Korean Company to Enter Canadian Dermal Filler Market 2024.12.12
more

Video

Select Opening of a Global Innovation Center Opening of a Global Innovation Center